Insulet Corporation (PODD)
NASDAQ: PODD · Real-Time Price · USD
339.88
+2.28 (0.68%)
At close: Aug 29, 2025, 4:00 PM
335.00
-4.88 (-1.44%)
After-hours: Aug 29, 2025, 6:38 PM EDT
Insulet Revenue
Insulet had revenue of $649.10M in the quarter ending June 30, 2025, with 32.88% growth. This brings the company's revenue in the last twelve months to $2.36B, up 25.99% year-over-year. In the year 2024, Insulet had annual revenue of $2.07B with 22.07% growth.
Revenue (ttm)
$2.36B
Revenue Growth
+25.99%
P/S Ratio
10.12
Revenue / Employee
$605,000
Employees
3,900
Market Cap
23.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.07B | 374.50M | 22.07% |
| Dec 31, 2023 | 1.70B | 391.80M | 30.02% |
| Dec 31, 2022 | 1.31B | 206.50M | 18.79% |
| Dec 31, 2021 | 1.10B | 194.40M | 21.49% |
| Dec 31, 2020 | 904.40M | 166.20M | 22.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
PODD News
- 5 days ago - Insulet Elevates Eric Benjamin to Chief Operating Officer - Business Wire
- 12 days ago - Insulet to Participate in Upcoming Investor Conferences - Business Wire
- 15 days ago - 20 stocks in the S&P 500 that are high achievers this earnings season - Market Watch
- 17 days ago - Insulet's Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold - Seeking Alpha
- 23 days ago - Insulet Lifts Annual Forecast On Increased Adoption For Insulin Pump Omnipod 5 - Benzinga
- 23 days ago - Insulet Corporation (PODD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Insulet beats second-quarter profit estimates on strong demand for insulin pumps - Reuters
- 23 days ago - Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1) - Business Wire